Redin Esther, Quintanal-Villalonga Álvaro, Rudin Charles M
Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Trends Cancer. 2024 Oct;10(10):935-946. doi: 10.1016/j.trecan.2024.07.008. Epub 2024 Aug 19.
Small cell lung cancer (SCLC) is a devastating disease with high proliferative and metastatic capacity. SCLC has been classified into molecular subtypes based on differential expression of lineage-defining transcription factors. Recent studies have proposed new subtypes that are based on both tumor-intrinsic and -extrinsic factors. SCLC demonstrates substantial intratumoral subtype heterogeneity characterized by highly plastic transcriptional states, indicating that the initially dominant subtype can shift during disease progression and in association with resistance to therapy. Strategies to promote or constrain plasticity and cell fate transitions have nominated novel targets that could prompt the development of more durably effective therapies for patients with SCLC. In this review, we describe the latest advances in SCLC subtype classification and their biological and clinical implications.
小细胞肺癌(SCLC)是一种具有高增殖和转移能力的毁灭性疾病。根据谱系定义转录因子的差异表达,SCLC已被分为分子亚型。最近的研究提出了基于肿瘤内在和外在因素的新亚型。SCLC表现出显著的肿瘤内亚型异质性,其特征是高度可塑性的转录状态,这表明最初占主导地位的亚型在疾病进展过程中以及与治疗耐药性相关时可能会发生转变。促进或限制可塑性和细胞命运转变的策略已经确定了新的靶点,这些靶点可能会推动为SCLC患者开发更持久有效的治疗方法。在这篇综述中,我们描述了SCLC亚型分类的最新进展及其生物学和临床意义。